SGLT2 Inhibitors and Hemoglobin: USMLE Meta-Analysis Review

A large systematic review and meta-analysis, led by internist-nephrologist Dr. Michele Eisenga and published in JAMA, found that SGLT2 inhibitors consistently raise hemoglobin and hematocrit. The analysis pooled 85 randomized trials with 70,543 participants. The authors also saw higher erythropoietin and lower ferritin and transferrin saturation. These are laboratory effects, and the clinical meaning is still uncertain.

What happened

SGLT2 inhibitors are widely used in type 2 diabetes, heart failure, and chronic kidney disease (CKD). Earlier trials had already hinted that patients on these drugs showed rising hemoglobin and hematocrit. The size of the effect and the mechanism were unclear.

Eisenga and colleagues (the JAMA paper lists Yaqin Yang as first author) pooled 85 randomized clinical trials. Participants had diabetes, cardiovascular disease, heart failure, or CKD. Comparators were placebo or other glucose-lowering drugs. Median follow-up was 24 weeks.

The main results:

• Hemoglobin was higher by an average of 0.60 g/dL versus controls.
• Hematocrit was higher by an average of 2.36% versus controls.
• The increase was described as modest but consistent across studies.
• Erythropoietin (EPO) concentrations were higher in patients on SGLT2 inhibitors.
• Transferrin saturation and ferritin were lower, while serum iron stayed largely unchanged.

The authors interpret the iron findings as a sign that the body mobilizes iron stores to support increased red blood cell production.

Why it matters

Anemia is common in CKD and heart failure. It reduces oxygen delivery and is tied to worse symptoms. SGLT2 inhibitors reduce cardiovascular and kidney events in these populations, so it is natural to ask whether the blood changes are part of the explanation.

This study does not answer that question. The source states plainly that the hemoglobin and hematocrit increases were relatively small. It is not yet clear whether they contribute directly to the cardiovascular and kidney benefits of these drugs. The findings are best read as a new clue about the biology of SGLT2 inhibitors. They are not evidence of a new clinical indication, and they are not a reason to treat anemia with these drugs. Further studies are needed to test whether changes in red cell production and iron metabolism play a direct role.

What to know for the USMLE

The study is a good hook for reviewing SGLT2 pharmacology and the physiology of erythropoiesis. The points below are standard textbook material, not findings of the meta-analysis.

• Mechanism: SGLT2 (sodium-glucose cotransporter 2) sits in the early proximal convoluted tubule (S1 segment) and reabsorbs most filtered glucose. Blocking it causes glucosuria, with modest osmotic diuresis and natriuresis. The effect is insulin-independent, so hypoglycemia risk is low when used without insulin or sulfonylureas.
• Drug names: The suffix is -gliflozin. Examples are empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
• Indications: Type 2 diabetes, heart failure (reduced and preserved ejection fraction), and CKD, including some patients without diabetes. Know that cardiorenal benefits are not simply a result of glucose lowering.
• Renal hemodynamics: More sodium reaches the macula densa. Tubuloglomerular feedback causes afferent arteriolar vasoconstriction and lowers intraglomerular pressure. This explains the small early eGFR dip and the long-term nephroprotection.
• Adverse effects (high-yield):
• Genital mycotic infections (candidal vulvovaginitis, balanitis), the most common
• Urinary tract infections, rarely urosepsis
• Euglycemic diabetic ketoacidosis, a classic exam trap with a normal or near-normal glucose
• Volume depletion and orthostatic hypotension, especially with loop diuretics
• Fournier gangrene (rare)
• An amputation signal with canagliflozin in CANVAS
• Glycemic efficacy falls as eGFR falls, because less glucose is filtered. Cardiorenal benefits persist.
• Erythropoietin physiology: EPO is made by peritubular interstitial fibroblasts in the renal cortex, with expression driven by hypoxia-inducible factor (HIF). Anemia of CKD is normocytic and normochromic, mainly from reduced EPO production. Low EPO is a classic CKD complication.
• Iron studies: Iron deficiency shows low ferritin, low serum iron, low transferrin saturation, and high TIBC. Anemia of chronic disease shows high hepcidin, high or normal ferritin, low serum iron, and low TIBC. In this meta-analysis, ferritin and transferrin saturation fell while serum iron was largely unchanged. This is a reminder that iron indices shift with changing erythropoietic demand, not only with deficiency.
• Hemoconcentration: Diuresis can raise hematocrit by reducing plasma volume. The summary does not tell us how much of the observed rise comes from this effect versus true red cell production. The EPO and iron findings suggest that increased erythropoiesis plays a role. Do not assume either explanation on a question stem unless it is stated.

Limitations

Several caveats apply, and the source material states some of them directly.

• Surrogate outcomes. Hemoglobin, hematocrit, EPO, ferritin, and transferrin saturation are laboratory measures. The article reports no evidence that these changes translate into better outcomes.
• Small absolute effect. An average rise of 0.60 g/dL is modest. It should not be extrapolated to treatment of anemia in individuals.
• Short follow-up. Median follow-up was 24 weeks. Longer-term behavior of hemoglobin and iron markers is not described in the source.
• Mixed populations and comparators. The trials included people with diabetes, cardiovascular disease, heart failure, and CKD, compared against placebo or other glucose-lowering agents. The source summary does not break down results by population or drug, so we cannot say whether the effect is the same for every patient group or every SGLT2 inhibitor.
• Mechanism remains inferred. The authors say the drugs "may influence" iron regulation and red cell production. The data are consistent with iron mobilization, but the study does not prove causation between these changes and clinical benefit.
• Press summary. This article is based on a news report of the JAMA paper. Details such as heterogeneity, subgroup analyses, and bias assessment are not in the source material and should be checked in the original publication.

FAQ

Do SGLT2 inhibitors raise hemoglobin?

In this meta-analysis of 85 randomized trials (70,543 participants), they did, by an average of 0.60 g/dL compared with controls. Hematocrit rose by 2.36%. The effect was modest but consistent across studies.

Why might SGLT2 inhibitors increase hematocrit?

The authors found higher erythropoietin levels along with lower ferritin and transferrin saturation. They suggest that the body mobilizes iron stores to support more red cell production. Diuresis and hemoconcentration are a separate textbook consideration, and the source does not quantify their contribution. The exact mechanism is still not established.

Is the rise in hemoglobin responsible for the heart and kidney benefits of SGLT2 inhibitors?

That is unknown. The source states that it is not yet clear whether the changes contribute directly to cardiovascular and kidney benefits. More studies are needed.

Key takeaways

• A JAMA meta-analysis of 85 randomized trials (70,543 participants) found that SGLT2 inhibitors raised hemoglobin by 0.60 g/dL and hematocrit by 2.36% over a median of 24 weeks.
• Erythropoietin rose while ferritin and transferrin saturation fell, with serum iron largely unchanged. This is consistent with iron mobilization for red cell production, but the clinical significance remains uncertain.
• For the USMLE, focus on the proximal tubule SGLT2 mechanism, the indications in T2DM, heart failure, and CKD, key adverse effects such as genital mycotic infections and euglycemic DKA, and the physiology of EPO and iron studies.